On October 19, 2025, Corcept Therapeutics announced that it presented new late‑breaking data from its pivotal Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The presentation focused on patients with platinum‑resistant ovarian cancer who had previously received or progressed on a PARP inhibitor (PARPi). The data showed a progression‑free survival (PFS) benefit, with a hazard ratio of 0.60 (p = 0.0035) for patients with prior PARPi treatment and 0.56 (p = 0.0046) for those whose disease progressed while on a PARPi, both yielding a median PFS of 7.36 months.
The safety profile of relacorilant plus nab‑paclitaxel was consistent with nab‑paclitaxel monotherapy, with no increase in the type, frequency, or severity of adverse events in the PARPi subgroups. These findings confirm the drug’s tolerability and reinforce the clinical benefit observed in the overall ROSELLA population, where relacorilant reduced the risk of disease progression by 30 % (HR = 0.70, p = 0.0076) and the risk of death by 31 % (HR = 0.69, p = 0.0121).
The data expand relacorilant’s therapeutic benefit to a population with a particularly poor prognosis and support the company’s strategy to evaluate the drug in earlier lines of ovarian cancer treatment. Corcept also announced the expansion of its Phase 2 BELLA trial to include additional study arms, including relacorilant plus nab‑paclitaxel and bevacizumab for platinum‑sensitive ovarian cancer and endometrial cancer. These developments position relacorilant as a potential new standard of care in ovarian cancer and accelerate the pathway toward regulatory approval and market adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.